Silex Systems expects growth

Silex Systems (ASX: SLX) last week announced an upbeat earnings result for the year ending 30 June. The company achieved a number of key milestones during the year, however still generated a net loss of $93,000, down 99.7% from the $31 million loss in FY12.

The company has four major divisions, SILEX Uranium Enrichment, Solar Systems, Translucent, and Chronologic. The SILEX Uranium Enrichment division was the major contributor to revenue and earnings. The division is responsible for marketing and developing the company’s “ground-breaking” SILEX uranium enrichment technology.

It received approval from the US Nuclear Registry in September 2012 for a licence to construct and operate a test facility in Wilmington, North Carolina, USA. Following the approval, the Phase 1 validation of the system was successfully undertaken, resulting in a $15 million milestone payment to Silex. This increased group revenue by 150% to $23 million for FY13 and was a key contributor to the reduction in net loss. Phase 1 involved demonstrating and validating the technology, with Phase 2 initiating the commercialisation of the technology.

Silex did not offer guidance on when Phase 2 and the final phase, number 3, would be complete, however the upbeat update indicates that the company is optimistic of the future of the technology.

The Solar Systems division, which operates Australia’s largest Concentrating Photovoltaic Solar Power Station, increased revenue by over 1,000% from $62,000 in FY12 to $747,000 in FY13. The loss from the division was $9 million, down from $11.6 million in FY12. The 1.5MW station provides enough power to service 500 average-sized homes and will be used to assess the commercial viability of the technology before a larger 100MW plant is installed at the same location. Construction of the plant is expected to start in late 2014 and has received conditional funding of $110 million from the Commonwealth and Victorian governments so far.

Finally, the Translucent and Chronologic divisions are research arms developing advanced semiconductor and USB technology, respectively. While generating little revenue at present, the company is hopeful that technological advances will advance to commercial production following customer evaluation in late 2013.

Foolish takeaway

Silex Systems is yet to commercialise its key technologies, but with Phase 2 development underway on its uranium enrichment process, and the commercial viability of solar panel technology being assessed, it can be reasonably expected that it will start to reward investors in the next 12 to 24 months. FY13 was much better for the company, however milestone payments for technology development will continue to play a large part in growing revenue until commercial production commences.

More interested in dividend yield than growth? Discover The Motley Fool’s favourite income idea for 2013-2014 in our brand-new, FREE research report, including a full investment analysis! Simply click here for your FREE copy of “The Motley Fool’s Top Dividend Stock for 2013-2014.”

More reading

Motley Fool contributor Andrew Mudie does not own shares in any of the companies mentioned in this article.

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.